Personalised medicine for multiple sclerosis care

Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination

(2016) Sudarshini Ramanathan et al.   AUTOIMMUNITY REVIEWS

TREATING MULTIPLE SCLEROSIS WITH CLADRIBINE

(2016) C Alvarez-Gonzalez et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

A pharmacogenetic study implicatesSLC9a9in multiple sclerosis disease activity

(2015) Federica Esposito et al.   ANNALS OF NEUROLOGY

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis

(2015) Tomas Kalincik et al.   ANNALS OF NEUROLOGY

Cerebrospinal fluid proteomics in multiple sclerosis

(2015) Ann C. Kroksveen et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Defining high, medium and low impact prognostic factors for developing multiple sclerosis

(2015) Mar Tintore et al.   BRAIN

Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β

(2015) Harald Hegen et al.   Expert Opinion on Drug Metabolism & Toxicology

Forecasting the Incidence of Dementia and Dementia-Related Outpatient Visits With Google Trends: Evidence From Taiwan

(2015) Ho-Wei Wang et al.   JOURNAL OF MEDICAL INTERNET RESEARCH

The prognostic value of CSF neurofilaments in multiple sclerosis at 15-year follow-up

(2015) A. Petzold   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Biologic efficacy optimization—a step towards personalized medicine

(2015) Patrick D. W. Kiely   RHEUMATOLOGY

Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways

(2015) E. T. Cirulli et al.   SCIENCE

Unmet needs of multiple sclerosis patients in the community

(2015) Roisin Lonergan et al.   Multiple Sclerosis and Related Disorders

Marginal Structural Cox Models for Estimating the Association Between β-Interferon Exposure and Disease Progression in a Multiple Sclerosis Cohort

(2014) Mohammad Ehsanul Karim et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Rheumatoid Arthritis Clinical Benefits from Abatacept, Cytokine Blockers, and Rituximab Are All Linked to Modulation of Memory B Cell Responses

(2014) G. J. SILVERMAN et al.   JOURNAL OF RHEUMATOLOGY

Multiple sclerosis genetics

(2014) Stephen Sawcer et al.   LANCET NEUROLOGY

Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis

(2014) Sandra Amor et al.   Multiple Sclerosis Journal

Economic costs associated with an MS relapse

(2014) K. O׳Connell et al.   Multiple Sclerosis and Related Disorders

Objectively Quantified Physical Activity in Persons With Multiple Sclerosis

(2013) Rachel E. Klaren et al.   ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION

MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials

(2013) Maria Pia Sormani et al.   LANCET NEUROLOGY

Clinically meaningful performance benchmarks in MS: Timed 25-Foot Walk and the real world

(2013) M. D. Goldman et al.   NEUROLOGY

Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan

(2012) Joanna Kitley et al.   BRAIN

Network Analysis of Randomized Controlled Trials in Multiple Sclerosis

(2012) Elias Zintzaras et al.   CLINICAL THERAPEUTICS

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis

(2011) S Vosslamber et al.   GENES AND IMMUNITY

Population Pharmacokinetics of Fingolimod Phosphate in Healthy Participants

(2011) Kai Wu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Validation of IRF5 as multiple sclerosis risk gene: putative role in interferon beta therapy and human herpes virus-6 infection

(2010) K Vandenbroeck et al.   GENES AND IMMUNITY

Personalized medicine in oncology: the future is now

(2010) Richard L. Schilsky   NATURE REVIEWS DRUG DISCOVERY

Brainstem lesions in clinically isolated syndromes

(2010) M. Tintore et al.   NEUROLOGY

Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis

(2009) A. Uzawa et al.   EUROPEAN JOURNAL OF NEUROLOGY

Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis

(2008) C Potter et al.   ANNALS OF THE RHEUMATIC DISEASES

Genome-Wide Pharmacogenomic Analysis of the Response to Interferon Beta Therapy in Multiple Sclerosis

(2008) Esther Byun et al.   ARCHIVES OF NEUROLOGY

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

(2008) L. K. Fisniku et al.   BRAIN

Review: Neutralizing antibodies against interferon-beta

(2008) Per Soelberg Sorensen   Therapeutic Advances in Neurological Disorders

In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent

(2007) A Sominanda et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY